BRPI0917491A2 - tratamento de hipertensao arterial pulmonar - Google Patents

tratamento de hipertensao arterial pulmonar

Info

Publication number
BRPI0917491A2
BRPI0917491A2 BRPI0917491A BRPI0917491A BRPI0917491A2 BR PI0917491 A2 BRPI0917491 A2 BR PI0917491A2 BR PI0917491 A BRPI0917491 A BR PI0917491A BR PI0917491 A BRPI0917491 A BR PI0917491A BR PI0917491 A2 BRPI0917491 A2 BR PI0917491A2
Authority
BR
Brazil
Prior art keywords
arterial hypertension
pulmonary arterial
hypertension treatment
treatment
pulmonary
Prior art date
Application number
BRPI0917491A
Other languages
English (en)
Inventor
Deborah Quinn
Steve Pascoe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917491(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0917491A2 publication Critical patent/BRPI0917491A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0917491A 2008-08-13 2009-08-11 tratamento de hipertensao arterial pulmonar BRPI0917491A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US16450109P 2009-03-30 2009-03-30
PCT/US2009/053358 WO2010019540A1 (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
BRPI0917491A2 true BRPI0917491A2 (pt) 2015-12-01

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917491A BRPI0917491A2 (pt) 2008-08-13 2009-08-11 tratamento de hipertensao arterial pulmonar

Country Status (16)

Country Link
US (1) US20110190313A1 (pt)
EP (1) EP2315592A1 (pt)
JP (1) JP2011530607A (pt)
KR (1) KR20110053354A (pt)
CN (1) CN102123711A (pt)
AU (1) AU2009282104A1 (pt)
BR (1) BRPI0917491A2 (pt)
CA (1) CA2732789A1 (pt)
CL (1) CL2011000295A1 (pt)
IL (1) IL210922A0 (pt)
MA (1) MA32617B1 (pt)
MX (1) MX2011001668A (pt)
NZ (1) NZ590839A (pt)
RU (1) RU2011109078A (pt)
TW (1) TW201010999A (pt)
WO (1) WO2010019540A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
AU2014205483B2 (en) 2013-01-10 2017-11-30 Gilead Sciences, Inc. Non-selective kinase inhibitors
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
CN106132403B (zh) 2013-10-11 2020-04-28 普尔莫凯恩股份有限公司 喷雾干燥制剂
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
CA3042123A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
CN114514016A (zh) 2019-05-16 2022-05-17 埃渃维特治疗学公司 伊马替尼调配物、制造和其用途
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
KR20230131179A (ko) 2020-11-17 2023-09-12 유나이티드 쎄러퓨틱스 코포레이션 폐 고혈압 분야를 위한 흡입형 이마티닙

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004037261A1 (en) * 2002-10-25 2004-05-06 The Administrators Of The Tulane Educational Fund Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CA2594687C (en) * 2005-01-28 2013-10-29 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
MX2007013738A (es) * 2005-05-02 2008-01-24 Novartis Ag Derivados de pirimidilaminobenzamida para sindrome hipereosinofilico.
BRPI0619416A2 (pt) * 2005-12-06 2011-10-04 Novartis Ag derivados de pirimidilaminobenzamida para o tratamento da neurofibromatose
EP2079729A1 (en) * 2006-11-03 2009-07-22 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
MX2011001668A (es) 2011-03-25
US20110190313A1 (en) 2011-08-04
CA2732789A1 (en) 2010-02-18
AU2009282104A1 (en) 2010-02-18
MA32617B1 (fr) 2011-09-01
WO2010019540A1 (en) 2010-02-18
RU2011109078A (ru) 2012-09-20
IL210922A0 (en) 2011-04-28
KR20110053354A (ko) 2011-05-20
TW201010999A (en) 2010-03-16
EP2315592A1 (en) 2011-05-04
CN102123711A (zh) 2011-07-13
CL2011000295A1 (es) 2011-07-15
JP2011530607A (ja) 2011-12-22
NZ590839A (en) 2013-02-22

Similar Documents

Publication Publication Date Title
BRPI0917491A2 (pt) tratamento de hipertensao arterial pulmonar
BRPI0916763A2 (pt) dialisador
DK2201858T3 (da) Hårtørrer
BRPI0906807A2 (pt) Fibra monofilamentar
BRPI0915524A2 (pt) conjunto de aerofólio
DK2318378T3 (da) Quinazolin-derivater
DK1987765T3 (da) Oximeter
BRPI0819362A2 (pt) Cesta-peneira
BRPI0915562A2 (pt) tamis melhorado
BRPI0915442A2 (pt) tamis melhorado
BRPI0912547A2 (pt) aba de fixação
BRPI0917718A2 (pt) calçado
ATE546371T1 (de) Holzbottich
SE0900474L (sv) Skördare
ES1069830Y (es) Yurta moderna
ES1067844Y (es) Burlete mejorado
ZA201100559B (en) Treatment of pulmonary arterial hypertension
BRPI0914456A2 (pt) "método para tratamento de hipertensão arterial pulmonar"
FI8241U1 (fi) Sykemittausjärjestely
FI20086069A (fi) Sykemittausjärjestely
FI8224U1 (fi) Kuivain
TH104535B (th) เครื่องเป่ามือ
TH104536B (th) เครื่องเป่ามือ
TH99749B (th) เครื่องเป่ามือ
FI20080064A0 (fi) Lumikenkä

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.